Marqibo
NDC Package 20536-322-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Marqibo is vincristine liposomal is used to treat a certain type of cancer called acute lymphoblastic leukemia. Marketed by Acrotech Biopharma Llc, this product is identified by NDC 20536-322 and is authorized under FDA application NDA202497.

Identification & Billing

NDC Package Code
20536-322-01
Package Description
1 KIT in 1 CARTON * 25 mL in 1 VIAL, GLASS (20536-325-01) * 5 mL in 1 VIAL, GLASS (20536-323-01) * 1 mL in 1 VIAL, GLASS (20536-324-01)
Product Code
20536-322
11-Digit Billing Format
20536032201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.

Clinical Specifications

Proprietary Name
Marqibo
Dosage Form
-
Usage Information
Vincristine liposomal is used to treat a certain type of cancer called acute lymphoblastic leukemia. It is a cancer chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Acrotech Biopharma Llc
FDA Application #
NDA202497
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-14-2013
End Marketing Date
10-26-2020
Listing Expiration
10-26-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 20536-322-01 identifies a specific commercial package of 1 kit in 1 carton * 25 ml in 1 vial, glass (20536-325-01) * 5 ml in 1 vial, glass (20536-323-01) * 1 ml in 1 vial, glass (20536-324-01) of Marqibo, labeled by Acrotech Biopharma Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Acrotech Biopharma Llc on January 14, 2013. The current certification is valid through October 26, 2020.

What are the primary indications for this medication?

Vincristine liposomal is used to treat a certain type of cancer called acute lymphoblastic leukemia. It is a cancer chemotherapy drug that works by slowing or stopping the growth of cancer cells.

How is this Acrotech Biopharma Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 20536032201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
20536-322-01
11-Digit CMS (5-4-2)
20536-0322-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.